SMA Capital’s Charles River Laboratories CRL Stock Holding History

SMA Capital’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-34	Closed	-$5.87K	–	136
2026 Q1	$5.87K	Buy	+34	New	+$6.3K	﹤0.01%	81

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

SMA Capital's CRL Position: Q2 2026 in Review

SMA Capital sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 34 shares — an estimated $5.87K sold.

SMA Capital first reported a position in CRL in Q1 2026 and held it in 1 quarter. The position peaked at $5.87K in Q1 2026. 567 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

SMA Capital reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
SMA Capital sold 34 Charles River Laboratories shares in Q2 2026, an estimated $5.87K.
SMA Capital first reported a position in Charles River Laboratories in Q1 2026 and held it in 1 quarter.
SMA Capital's Charles River Laboratories position peaked at $5.87K in Q1 2026.
567 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.